Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Change in Accured Expenses (2016 - 2025)

Dare Bioscience (DARE) has disclosed Change in Accured Expenses for 11 consecutive years, with $149269.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 91.48% year-over-year to $149269.0, compared with a TTM value of $553391.0 through Sep 2025, up 107.02%, and an annual FY2024 reading of $520816.0, up 106.3% over the prior year.
  • Change in Accured Expenses was $149269.0 for Q3 2025 at Dare Bioscience, down from $1.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.8 million in Q4 2022 and bottomed at -$8.3 million in Q4 2023.
  • Average Change in Accured Expenses over 5 years is $23657.8, with a median of $43036.5 recorded in 2024.
  • The sharpest move saw Change in Accured Expenses soared 3809.3% in 2021, then crashed 428.76% in 2022.
  • Year by year, Change in Accured Expenses stood at -$640500.0 in 2021, then soared by 1155.06% to $6.8 million in 2022, then plummeted by 222.41% to -$8.3 million in 2023, then surged by 101.64% to $135384.0 in 2024, then increased by 10.26% to $149269.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for DARE at $149269.0 in Q3 2025, $1.4 million in Q2 2025, and -$1.1 million in Q1 2025.